1. Scrip

Antibody Drugs Could Be Next COVID-19 Milestone

DARPA Saw The Pandemic Coming – Can AbCellera Investment Pay Off?

 
• By Andrew McConaghie

Working with the US agency for two years, AbCellera was primed to respond, and is competing with Vir and Regeneron to bring a COVID-19 therapy to patients before the end of 2020.

Hudson_Park_NY
New York, 2 May 2020: Social distancing has helped flatten the curve, but can't go on indefinitely. Antibody drugs could arrive by late 2020, ahead of vaccines to help tackle COVID-19.

Now that Gilead Sciences Inc.’s remdesivir has gained emergency use authorization from the US Food and Drug Administration, the next hoped-for milestone ahead of a vaccine could be an antibody-based treatment.

These could play an especially important role, as they could be developed faster than vaccines, and even serve as a short term stand-in for a vaccine, but also as a

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D